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Abstract
Background
Detection of lung cancer at an early stage by sensitive screening tests could be an impor-
tant strategy to improving prognosis. Our objective was to identify a panel of circulating
microRNAs in plasma that will contribute to early detection of lung cancer.
Material and Methods
Plasma samples from 100 early stage (I to IIIA) non–small-cell lung cancer (NSCLC) pa-
tients and 100 non-cancer controls were screened for 754 circulating microRNAs via qRT-
PCR, using TaqMan MicroRNA Arrays. Logistic regression with a lasso penalty was used to
select a panel of microRNAs that discriminate between cases and controls. Internal valida-
tion of model discrimination was conducted by calculating the bootstrap optimism-corrected
AUC for the selected model.
Results
We identified a panel of 24 microRNAs with optimum classification performance. The com-
bination of these 24 microRNAs alone could discriminate lung cancer cases from non-can-
cer controls with an AUC of 0.92 (95% CI: 0.87-0.95). This classification improved to an
AUC of 0.94 (95% CI: 0.90-0.97) following addition of sex, age and smoking status to the
model. Internal validation of the model suggests that the discriminatory power of the panel
will be high when applied to independent samples with a corrected AUC of 0.78 for the 24-
miRNA panel alone.
Conclusion
Our 24-microRNA predictor improves lung cancer prediction beyond that of known
risk factors.
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Introduction
Lung cancer is the most common cause of cancer death worldwide. In 2012, 1.82 million new
cases, and 1.59 million deaths due to lung cancer were recorded, representing 13% of all cancer
cases and 19% of all cancer deaths respectively [1]. Non-small cell lung cancer (NSCLC) ac-
counts for approximately 80–85% of all lung cancer cases and comprises primarily two histo-
logical types: adenocarcinoma (AC) and squamous cell carcinoma (SCC). In spite of advances
in therapy, an overall 5-year survival rate of only 16% [2] is mostly due to late stage at diagno-
sis. Detection of lung cancer at an early stage by sensitive screening tests could be an important
strategy to improve lung cancer prognosis.
The National Lung Screening Trial (NLST) using low-dose helical computed tomography
(LDCT) in high-risk individuals demonstrates that a 20% reduction in lung cancer-specific
mortality and a 6.7% reduction in all-cause mortality [3] can be achieved. Nevertheless, high
false-positive rates of NLST [4], costs, and potential harms from radiation exposure highlight
the need for simpler, non-invasive and more accessible methodologies for effective early cancer
detection as complementary biomarkers.
MicroRNAs (miRNAs) are a group of small (~22-nucleotides long) non-coding, single-
stranded RNAs that regulate gene expression post-transcriptionally. Aberrations in miRNA ex-
pression levels have been found in relation to oncogenesis and tumour metastasis [5], including
NSCLC. More than 2500 human miRNAs sequences are currently known [6]. Several studies
have shown that serum and plasma miRNAs (called circulating miRNAs) present great prom-
ise as novel non-invasive biomarkers for the early diagnosis of various cancers due to their ease
of access, and long term stability [7,8]. In lung cancer, several miRNA expression profiles have
been identified with remarkably high predictive values including a 34-miRNA diagnostic signa-
ture with an AUC of 0.89 [9], a 10-miRNA panel with an AUC of 0.97 in serum as well as
16-miRNA ratios as a signature of risk (AUC: 0.85) and diagnosis (AUC: 0.88) [10,11] in plas-
ma samples of NSCLC patients.
Previous studies have shown substantial inconsistencies although these were based on limit-
ed sample sizes or used candidate miRNA approaches. Additionally, a level of controversy ex-
ists in that miRNAs identified in the blood merely indicate changes in blood cells secondary to
an overall poor health condition and are not specific to the presence of cancer in a target organ.
Although the measurement of miRNA expression in plasma or serum has been postulated as a
promising approach in diagnosing lung cancer, the concept requires further investigations to
demonstrate its potential use as a clinical application. There is no strong evidence as to whether
serum or plasma is superior for miRNA evaluation, however, recent reports suggest that plas-
ma may be the preferred sample choice given that RNA released during the coagulation process
may alter the composition of circulating miRNAs in serum samples [12].
Here, we present a genome-wide miRNA expression screen in plasma samples from 100
NSCLC cases and 100 controls in which we determined a miRNA signature with a high diag-
nostic value that was identified through stringent statistical approaches.
Results
Study population
The characteristics of 200 study participants, including 65 patients with lung SCC, 35 patients
with lung AC and 100 controls are presented in Table 1. There was a difference in sex (more
men among the cases), age at interview (cases were on average 1.5 years older than controls),
smoking status (15% more current smokers among cases) and alcohol drinking status (cases in-
cluded 12% more former alcohol consumers). Lung cancer patients were of an early IA—IIIA
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stage. The mean follow-up time was 2.48 years. During this follow-up period, 64 of the 100
cases died and 36 were still alive at censoring.
Micro-RNA profiles in plasma
To evaluate whether specific miRNA signatures are detectable in plasma samples of patients
with early stages of NSCLC, we performed a high-throughput screen of 754 miRNAs using
TaqMan Human MicroRNA Arrays. On average 235 and 115 miRNAs were detected on Card
A and Card B, respectively (present in at least 80 out of 200 samples in either cases or controls)
(Fig 1). The miRNA expression profiles in plasma were quantile normalized and subjected to
differential expression analyses between NSCLC samples and controls. Of 350 detected miR-
NAs in plasma, 61 miRNAs were found to be significantly differentially expressed between
lung cancer cases and controls (35 on Card A, 26 on Card B) including 33 upregulated and 28
downregulated miRNAs (p-value< 0.05). These comprised 21 miRNAs differentially express-
ed with significant adjusted p-value corrected for multiple testing (Table 2). Despite the
Table 1. Select baseline characteristics of the study population (lung cancer cases and controls) recruited in the IARC case-control study (Mos-
cow, Russia, 2006–2012).
Characteristics Cases Controls p valuea
N = 100 N = 100
Sex 0.010
Female 14 29
Male 86 71
Age at interview, mean (SD) 62.6 (7.5) 60.1 (9.7) 0.037
Smoking status <0.001
Never 11 40
Former 27 12
Current 62 48
Pack-years (among smokers only) mean (SD) 47.8 (22.5) 29.8 (15.2) <0.001
Alcohol drinking status 0.029
Never 23 36
Former 23 11
Current 54 53
Body mass index (BMI) [kg/m2] mean (SD) 26.2 (4) 27.3 (4.7) 0.058
Histological type
Squamous cell carcinoma 65 ———-
Adenocarcinoma 35 ———-
Clinical stage
IA 16 ———-
IB 33 ———-
IIA 6 ———-
IIB 15 ———-
IIIA 30
Years of follow-up, mean (SD) 2.48 (1.69) ———-
Vital status at the end of follow-up
Dead 64 ———-
Alive 36 ———-
a p value calculated using χ2 test for categorical variables and Student’s t-test for continuous variables.
doi:10.1371/journal.pone.0125026.t001
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significant differential expression, supervised hierarchical clustering analysis showed that this
set of 61 miRNAs was not able to clearly distinguish between lung cancer cases and controls
(S1 Fig).
Prediction models
To select a panel of miRNAs discriminating between cases and controls, a logistic regression
model with lasso penalty was fitted. This analysis identified a panel of 24 plasma miRNAs with
an optimum classification performance (S2 and S3 Figs). Table 3 shows the complete list of se-
lected miRNAs within the panel. Multiple logistic regression analysis showed that combination
of the 24 miRNAs alone could discriminate lung cancer cases from controls with very high
AUC of 0.92 (95%CI: 0.87–0.95). In the logistic model including the 24-miRNA panel and ad-
justed for main lung cancer risk factors, namely sex, age at interview and smoking status, the
classification improved to an AUC of 0.94 (95%CI: 0.90–0.97) (Fig 2). The improvement in the
magnitude of discrimination attributable to the 24-miRNA panel is substantial compared with
that of the main lung cancer risk factors alone. The AUCs for the full logistic models with and
without the 24-miRNA panel were 0.94 (95%CI: 0.90–0.97) and 0.72 (95%CI: 0.65–0.78), re-
spectively (Fig 3). The predictive value was of similar magnitude (AUC: 0.95; 95%CI: 0.91–
0.98) when replacing the categorical smoking status variable by the continuous pack-years vari-
able. Notably, even though derived from both histological types, the 24-miRNA panel per-
formed equally well in both ACs (AUC: 0.94) and SCCs (AUC: 0.96). Similarly, the predictor
performed well for cancers of all stages (IA-IIIA), with an AUC of 0.96 for stage I (IA and IB;
n = 49) patients, 0.98 for stage II (stage IIA and IIB; n = 21) patients and 0.97 for stage IIIA
(n = 30) patients (data not shown).
Internal validation of the selected 24-miRNA panel model (i.e., validation accounting for
variability due to parameter estimation) using the bootstrap optimism corrected AUC suggests
that the discriminatory power of the panel will be high when applied to independent samples
(corrected AUC of 0.86 for the 24-miRNA panel alone, 0.87 for the model including sex, age
and smoking status and 0.89 for the model with pack-years variable). The bootstrap optimism
Fig 1. MiRNA detected in plasma samples of 100 patients with lung cancer vs 100 controls on TaqManmicroRNACARD A and CARDB,
respectively in the IARC case-control study (2006–2012).
doi:10.1371/journal.pone.0125026.g001
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Table 2. Complete list of significant differentially expressedmiRNA (p-value < 0.05) in lung cancer pa-
tients as compared with controls in the IARC case-control study (Moscow, Russia, 2006–2012)—glob-
al miRNA expression profiling using TaqMan HumanMicroRNAArray A + B Card Set (v3.0).
miRNA p-valuea adj. p-valueb FC TLDA card
miR-340#-002259 5.99E-06 0.0006 2.92 B
miR-218-000521 6.68E-06 0.0010 0.29 A
miR-450b-5p-002207 1.04E-05 0.0010 0.31 A
miR-566-001533 0.0003 0.0144 0.30 B
miR-661-001606 0.0005 0.0160 0.36 B
miR-200c-002300 0.0004 0.0212 2.65 A
miR-323-3p-002227 0.0005 0.0212 0.55 A
miR-642-001592 0.0007 0.0212 0.43 A
miR-28-000411 0.0007 0.0212 1.91 A
miR-1290-002863 0.0011 0.0264 0.54 B
miR-590-3P-002677 0.0012 0.0264 2.29 B
miR-485-3p-001277 0.0012 0.0331 0.56 A
miR-22#-002301 0.0021 0.0364 2.18 B
miR-191#-002678 0.0027 0.0402 2.88 B
miR-26b#-002444 0.0039 0.0442 3.08 B
miR-34b-002102 0.0042 0.0442 0.39 B
miR-425#-002302 0.0043 0.0442 2.24 B
miR-766-001986 0.0046 0.0442 1.65 B
miR-203-000507 0.0019 0.0445 0.37 A
miR-193a-5p-002281 0.0024 0.0474 0.49 A
miR-25-000403 0.0025 0.0474 0.62 A
miR-517b-001152 0.0033 0.0515 0.28 A
miR-487a-001279 0.0033 0.0515 0.40 A
miR-1275-002840 0.0065 0.0571 0.42 B
miR-122-002245 0.0041 0.0591 0.53 A
miR-378-000567 0.0078 0.0638 0.43 B
miR-146a-000468 0.0059 0.0775 1.78 A
miR-483-5p-002338 0.0065 0.0775 0.52 A
miR-484-001821 0.0066 0.0775 1.90 A
miR-93#-002139 0.0113 0.0857 1.73 B
miR-652-002352 0.0103 0.1064 1.70 A
miR-708-002341 0.0105 0.1064 0.38 A
miR-339-3p-002184 0.0107 0.1064 1.64 A
miR-200a-000502 0.0118 0.1086 0.46 A
miR-182-002334 0.0121 0.1086 0.56 A
miR-1243-002854 0.0176 0.1241 0.37 B
let-7f-000382 0.0150 0.1278 3.13 A
miR-151-3p-002254 0.0215 0.1390 1.63 B
miR-1271-002779 0.0235 0.1390 1.75 B
miR-454#-001996 0.0236 0.1390 1.84 B
let-7b-002619 0.0188 0.1488 1.33 A
miR-140-001187 0.0190 0.1488 1.52 A
miR-26a-000405 0.0217 0.1632 1.36 A
miR-155-002623 0.0226 0.1633 1.54 A
miR-645-001597 0.0305 0.1702 0.56 B
(Continued)
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corrected AUC which took into account the entire miRNA classifier selection process (penal-
ized Lasso logistic regression) was 0.78.
Discussion
Despite extensive advancements of imaging and combined treatment modalities, the 5-year
survival rate of lung cancer has improved only marginally over recent decades [2]. A non-inva-
sive, biomarker-driven stratification of early-stage lung cancer could therefore complement
LDCT screening and improve therapy management. We have developed a panel of 24 plasma
miRNAs capable of discriminating early stage NSCLC cases from controls with a high AUC of
0.92 after screening 754 miRNAs in 100 NSCLC patients and 100 non-cancer individuals. This
set of miRNAs was identified through very stringent statistical methods. To our knowledge this
is also one of the largest exploratory studies of miRNA in plasma. Tests such as these demon-
strate several advantages in the clinical setting including no requirement for invasive sample
collection (“liquid biopsy”), low cost when compared to imaging techniques, straightforward
laboratory procedures and inclusion of a panel of biomarkers instead of a single miRNA.
To date, several studies have reported miRNA profiles in plasma and serum developed for
the diagnosis of NSCLCs [9–11,13–16]. Despite very promising results these studies have
shown a rather small overlap between identified miRNA signatures, and were based on limited
sample sizes/pools of samples which did not allow for assessment of the contribution by a sin-
gle patient to the genetic pool, or used a candidate miRNA approach for discovery of the
miRNA panel. The variation in pre-analytical factors, such as sample preparation procedures,
and different normalization strategies makes comparison between studies difficult. Also the
differences in miRNA profiles between serum and plasma [14] may account for some of the
lack of correlation of miRNA expression levels between previous studies. Lastly, the described
signatures could differ because of the inherent multitude of miRNA targets and their potential
Table 2. (Continued)
miRNA p-valuea adj. p-valueb FC TLDA card
miR-191-002299 0.0249 0.1728 1.35 A
miR-221-000524 0.0261 0.1728 1.46 A
miR-18a-002422 0.0267 0.1728 1.75 A
miR-1285-002822 0.0332 0.1757 0.34 B
miR-30d#-002305 0.0385 0.1802 1.90 B
miR-130b#-002114 0.0407 0.1802 2.14 B
miR-7#-001338 0.0418 0.1802 1.37 B
miR-30a-3p-000416 0.0425 0.1802 1.57 B
miR-335#-002185 0.0425 0.1802 1.64 B
miR-1233-002768 0.0452 0.1842 0.46 B
miR-495-001663 0.0315 0.1953 0.44 A
miR-758-001990 0.0322 0.1953 0.56 A
miR-223-002295 0.0425 0.2497 1.51 A
miR-411-001610 0.0479 0.2676 0.60 A
miR-19b-000396 0.0493 0.2676 1.54 A
miR-26b-000407 0.0498 0.2676 1.48 A
a Limma analysis non-adjusted p-value.
b p-value corrected for multiple testing (Benjamini-Holm method).
FC: fold change (> 1 increased; < 1 decreased expression in lung cancer patients vs. non-cancer controls).
doi:10.1371/journal.pone.0125026.t002
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redundancy. Given that our study evaluated the highest number of miRNA profiles, we were
able to assess the predictive value of previously reported miRNA signatures in our data. Inter-
estingly, despite small overlap of miRNAs between predictors, different population of patients,
sample processing, extraction protocols and normalization procedures used when compared to
earlier studies [9,10,13], a relatively high predictive value (AUC: 0.68–0.78) of these miRNA
panels was observed in our study (S1–S4 Tables, S4 Fig), thus highlighting the potential of cir-
culating miRNAs as biomarkers for lung cancer detection. In our data, the best discrimination
between NSCLC cases and controls was found for the 34-miRNA signature reported by Bianchi
and colleagues [9] showing an AUC of 0.78 (95%CI: 0.72–0.84). Lower predictive value was ob-
served when using the signature of risk (developed in pre-diagnostic samples) and diagnosis
Table 3. Logistic regression predictionmodel with the 24-microRNA panel for patients with lung cancer vs controls in the IARC case-control
study (Moscow, Russia, 2006–2012).
Variable ORa (95%CI) P valuea ORb (95%CI) P valueb
Sex ———- ———- 1.80 (0.37–8.74) 0.466
Age at interview ———- ———- 1.02 (0.95–1.09) 0.578
Smoking status ———- 0.003
Never ———- Reference
Former ———- 24.46 (3.33–179.8)
Current ———- 19.09 (3.19–114.2)
hsa-let-7c-000379 0.75 (0.56–1.00) 0.051 0.71 (0.50–0.99) 0.043
hsa-miR-122-002245 1.16 (0.93–1.46) 0.196 1.17 (0.89–1.53) 0.273
hsa-miR-182-002334 1.32 (1.04–1.67) 0.021 1.36 (1.03–1.79) 0.029
hsa-miR-193a-5p-002281 1.14 (0.92–1.42) 0.220 1.07 (0.85–1.35) 0.538
hsa-miR-200c-002300 0.81 (0.68–0.98) 0.029 0.89 (0.73–1.10) 0.274
hsa-miR-203-000507 1.12 (0.95–1.32) 0.168 1.10 (0.92–1.31) 0.291
hsa-miR-218-000521 1.24 (1.02–1.52) 0.033 1.13 (0.91–1.39) 0.272
hsa-miR-155-002623 0.84 (0.64–1.00) 0.202 0.84 (0.63–1.12) 0.238
hsa-let-7b-002619 0.95 (0.61–1.48) 0.826 0.96 (0.58–1.58) 0.878
hsa-miR-411-001610 1.37 (1.12–1.68) 0.002 1.41 (1.13–1.75) 0.002
hsa-miR-450b-5p-002207 1.37 (1.11–1.70) 0.003 1.52 (1.19–1.94) 0.001
hsa-miR-485-3p-001277 1.40 (0.97–2.01) 0.072 1.34 (0.91–1.99) 0.141
hsa-miR-519a-002415 1.22 (1.05–1.42) 0.011 1.20 (1.01–1.42) 0.044
hsa-miR-642-001592 1.13 (0.93–1.37) 0.221 1.29 (1.03–1.62) 0.026
hsa-miR-517b-001152 1.07 (0.95–1.21) 0.260 1.10 (0.96–1.27) 0.169
hsa-miR-520f-001120 1.06 (0.99–1.13) 0.113 1.10 (1.01–1.18) 0.021
hsa-miR-206-000510 0.85 (0.74–0.99) 0.033 0.90 (0.76–1.06) 0.203
hsa-miR-566-001533 1.10 (0.95–1.26) 0.197 1.02 (0.86–1.21) 0.817
hsa-miR-661-001606 1.10 (0.94–1.30) 0.240 1.15 (0.96–1.39) 0.130
hsa-miR-340#-002259 0.74 (0.57–0.97) 0.030 0.71 (0.52–0.96) 0.027
hsa-miR-1243-002854 1.09 (0.97–1.22) 0.139 1.10 (0.97–1.26) 0.131
hsa-miR-720-002895 1.95 (1.39–2.73) <0.001 1.89 (1.28–2.80) 0.001
hsa-miR-543-002376 1.11 (0.95–1.30) 0.170 1.15 (0.97–1.36) 0.112
hsa-miR-1267-002885 0.94 (0.88–1.00) 0.048 0.95 (0.88–1.01) 0.114
a Model containing the 24-miRNA panel (continuous, normalized Ct values).
b Model containing sex (Male, Female), age at interview (continuous), smoking status (Never, Former, Current) and the 24-miRNA panel (continuous,
normalized Ct values).
Abbreviations: OR, odds ratio; CI, conﬁdence interval.
doi:10.1371/journal.pone.0125026.t003
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Fig 2. Evaluation of the performance of the 24-miRNA classifier (left) and a classifier including the 24-miRNA panel, age at recruitment, sex and
smoking status (right) assessed using area under Receiver Operating Characteristics (ROC) curves (AUCs) in the IARC case-control study (2006–
2012).
doi:10.1371/journal.pone.0125026.g002
Fig 3. Evaluation of the performance of the model including age at recruitment, sex and smoking
status (red) and a classifier including 24-miRNA panel, age at recruitment, sex and smoking status
(blue) assessed using the area under Receiver Operating Characteristics (ROC) curves (AUCs) in the
IARC case-control study (2006–2012).
doi:10.1371/journal.pone.0125026.g003
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(developed in case-control study) described by Boeri and colleagues [10] and recently validated
by the same group [11] showing an AUC of 0.71 (95%CI: 0.65–0.78) and AUC of 0.70 (95%CI:
0.63–0.76), respectively. Finally, the 10-miRNA panel defined by Chen and colleagues yielded
an AUC of 0.68 (95%CI: 0.61–0.74) when fitted using our data [13].
Previous reports raised the question whether miRNAs found in circulation originate from
tumours. In theory, miRNA in plasma or serum can originate from the tumour or from inflam-
matory host responses. In the absence of miRNA data from tumour tissue in our set of samples
we compared a panel of 24 miRNAs in our predictor to differentially expressed miRNA from
AC and SCC of the lung obtained via analysis of the Cancer Genome Atlas (TCGA) miRNA se-
quencing data (https://tcga-data.nci.nih.gov/tcga/). Twelve of the miRNA included in our pre-
dictor were also altered in TCGA data in either histology. However, the direction of association
was consistent only for let-7c and miR-218. This suggests that a predictive role of plasma miR-
NAs is independent from tissue in line with previous findings of Boeri and colleagues [10].
Recent studies have also suggested that significant variations in abundance of microRNA
biomarkers reported in the literature might be a result of the inclusion of haemolyzed samples
[17–19]. To minimize the effect of haemolysis, the samples used in our study followed stan-
dardized protocols and were processed within 2 hours from the time of blood collection. In ad-
dition, a QC step was implemented to assess potential haemolysis by evaluation of expression
levels of 10 previously reported haemolysis-related miRNA, including miR-451, miRNA miR-
16, miR-15b, miR-486-3p, miR-532-3p, miR-886-5p, miR-636, miR-1255B, RNU48 and miR-
92a [17,19] among all miRNAs detected in our study. We did not observe significant differ-
ences in the haemolysis-related miRNA between lung cancer cases and controls in our series
except for miR-15b (p-value = 0.024) (S5 Table). However, alterations of miR-15b have been
previously reported in tumour tissues [20,21] and miR-15b has been proposed as a serum bio-
marker for detection of NSCLC[22]. Moreover, none of the haemolysis-related miRNAs were
present in our 24-miRNA predictor.
Our study has several noteworthy strengths, including: careful selection of patients with all
clinical data available, standardized and uniform processing of blood samples within 2 hours
from blood collection, ultracentrifugation step following defreezing to remove cryoprecipitates
and cell debris, large sample size, large number of miRNAs analyzed and very rigorous statisti-
cal assessment of the miRNA predictor. Known predictors of lung cancer were forced into
models in the study regardless of statistical significance to truly test the added incremental
value of our 24-miRNA panel (Fig 3).
A limitation is that, due to the case-control design of our study, blood samples were collect-
ed at the time of diagnosis. To partially address this constraint we did restrict our analysis to
early stage NSCLC. Also our study lacks an external validation series. To tackle this concern we
performed internal validation using a bootstrapping method which indicated that the predic-
tive value of the panel will remain high when applied to an independent series of samples.
The small size of mature miRNAs and their sequence homology to precursor miRNA re-
quires sensitive methods for quantitative analysis. We used the current “gold standard”method
for measurement of circulating miRNAs. TaqMan MiRNA Cards use a target-specific, stem-
loop reverse transcription primer to address the challenge of the short length [23]. Despite the
high accuracy and specificity of the qRT-PCR technique, each miRNA expression level mea-
sured can be influenced by both systematic experimental bias and technical variations includ-
ing differences in sample procurement, stabilization, RNA extraction, and sample differences.
As a result, data normalization is critical to minimize “noise” and obtain biologically meaning-
ful data and to develop miRNA-based biomarkers. In the absence of stably expressed endoge-
nous circulating miRNAs to function as normalization controls, and to verify the sensitivity of
our results several normalization strategies were tested in our study, including quantile
Circulating miRNAs for Early Detection of Lung Cancer
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normalization, rank normalization, geometric mean normalization, normalization to endoge-
nous U6snRNA control and to the ath-miR-159a spike-in exogenous control. Based on explor-
atory data analysis plots, instability of endogenous control, difference in abundance of spike-in
vs sample miRNA, we decided to quantile normalization was chosen for the analysis. In addi-
tion, to reduce confounding from technical variation such as plate-to-plate variation and varia-
tion due to purification, we distributed samples such that diagnostic variables were balanced
with respect to day of analysis or plate number and randomized within each day and plate.
In summary, our study demonstrates that the 24-miRNA panel is significantly and indepen-
dently associated with lung cancer following analysis of a liquid biopsy and adds to lung cancer
prediction beyond that contributed by established risk factors. Our study should therefore be
seen as an exploratory study providing a strong and highly predictive miRNA panel identified
through rigorous statistical approaches for further validation in well-designed large prospective
cohorts and screening trials. If current findings are validated, it is expected to make important
contributions to clinical and public health practice and may lead to more efficient lung cancer
screening by improving enrolment criteria for identifying those who would benefit from
further screening.
Patients and Methods
Study population
Lung cancer patients and controls were recruited through an IARC case-control study coordi-
nated in Moscow from 2006 to 2012. Cases were incident cancer patients collected from the
Russian N.N.Blokhin Cancer Research Centre and Moscow City Clinical Oncology Dispensary
serving Moscow and the surrounding regions. Controls were recruited from individuals visiting
two Moscow general hospitals for disorders unrelated to lung cancer and to associated risk fac-
tors. All study participants provided written informed consent and were interviewed.
Peripheral blood was collected in EDTA tubes at the time of interview and processed as rap-
idly as possible (generally within 2 hours). For cases, blood draw was performed before surgery
and any adjuvant treatment. Plasma samples were isolated by centrifugation of whole blood at
2000xg for 10 minutes at room temperature. Samples were stored at −80°C. All specimens were
obtained in accordance with the declaration of Helsinki guidelines and were approved by the
local Institutional Review Board and the IARC Ethics Committee. A total of 100 lung cancer
cases and 100 controls were included (Table 1).
RNA isolation
After thawing, plasma samples were centrifuged at 16,000 x g for 5 minutes to remove cryopre-
cipitates and cell debris. Total RNA was isolated from 300μL of plasma using NucleoSpin
miRNA Plasma kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s pro-
tocol with Proteinase K digest, addition of 2μg of glycogen carrier and DNAse digest steps. All
samples were spiked-in with 10pmol of Arabidopsis thaliana synthetic miR-159a (synthesized
by Eurofins MWGOperon, Ebersberg, Germany) to control for variations in the RNA prepara-
tion step. Purified RNA was kept at −80°C before being used for reverse transcription.
Profiling by TaqMan Human MicroRNA Arrays
Expression levels of 754 miRNAs (Sanger miRBase v14) were quantified using the TaqMan
Human MicroRNA Array A + B Card Set v3.0 (Applied Biosystems, Foster City, CA) as per
the manufacturer's instructions (including pre-amplification) (S1 Methods). Quantitative miR-
NAs expression data were acquired by ABI 7900HT SDS software v2.4. Cycle threshold (Ct,
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cycle in which there is the first detectable significant increase in fluorescence) values were set
using ExpressionSuite software (Applied Biosystems) on the first 60 samples (automatic base-
line and threshold) and these thresholds for Ct were used for the remaining series. The Taq-
Man Human MicroRNA Array experiments are MIAME compliant and have been deposited
at the NCBI Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo)
under accession GSE64591.
Statistical analysis
Descriptive comparisons of study variables between cases and controls used the Chi-squared
test for categorical data, and the Student's t-test for continuous data. The data were analysed in
HTqPCR package [24] using R Bioconductor [25]. miRNAs with undetermined Ct values in
more than 120 samples were filtered out. Data were quantile normalized. Following normaliza-
tion Ct values with an interquartile range (IQR) of less than 1.5 and endogenous controls were
removed from subsequent analysis, and limma analysis was performed to identify differentially
regulated miRNA between cases and controls. With limma, a one-factorial linear model is fit-
ted for each miRNA and the standard errors (SE) are moderated using an empirical Bayes
model resulting in moderated t-statistics for each miRNA [26]. P-values of less than 0.05 were
considered statistically significant. We also report adjusted p-values corrected for multiple test-
ing using the Benjamini-Holm method to control for the false positive error rate. Logistic re-
gression with a lasso penalty (with penalty parameter tuning conducted by 20-fold cross-
validation) was used to select a panel of miRNAs for discriminating between cases and con-
trols. Logistic regression models were used to evaluate whether the 24-miRNA panel was asso-
ciated with lung cancer after adjustment for known risk factors for lung cancer (age, sex and
smoking status). The area under the receiver operating characteristic curve (AUC) was calcu-
lated to assess the discriminatory power of the model. Internal validation of the selected model
was conducted by calculating the bootstrap optimism-corrected AUC. This correction ac-
counts for overfitting of the model parameters for the selected model. Additionally, an opti-
mism-correct AUC was calculated based on bootstrapping the entire model selection process.
This accounts for overfitting in both model selection and parameter estimation. All analyses
were performed by using STATA v11 (STATA, College Station, TX) and R [25]. All presented
p-values are two-sided.
Supporting Information
S1 Fig. Hierarchical classification of 61 significant differentially expressed microRNAs (p-
value< 0.05) in lung cancer patients as compared with controls.NSCLC cases are highlight-
ed in red.
(TIF)
S2 Fig. Optimal lambda value and cross validated error plot for the Lasso logistic regression
analysis.
(TIF)
S3 Fig. Box plots of the 24 plasma miRNAs included in the panel in lung cancer patients
and controls in the IARC case-control study (2006–2012). The median score is the line in the
middle of the box and the 25th and 75th percentile are the lower and upper part of the box. The
whiskers extend to the most extreme point no longer than 1.5 times the interquartile range
away from the box. Outliers are given as dots.
(TIF)
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S4 Fig. Assessment of the predictive value of previously described multi-miRNA signatures
for an early detection of NSCLC patients in the IARC case-control study dataset (2006–
2012).
(TIF)
S1 Methods. Supplementary methods.
(DOCX)
S1 Table. Logistic regression prediction model with the microRNA panel reported by Bian-
chi F et al (2011) [9] evaluated in the IARC case-control study (2006–2012).
(DOCX)
S2 Table. Logistic regression prediction model with the microRNA panel reported by Chen
X et al (2012) [13] evaluated in the IARC case-control study (2006–2012).
(DOCX)
S3 Table. Logistic regression prediction model with the 16-microRNA ratio signature of
risk reported by Boeri M et al (2011) [10] evaluated in the IARC case-control study (2006–
2012).
(DOCX)
S4 Table. Logistic regression prediction model with the 16-microRNA ratio signature of di-
agnosis reported by Boeri M et al (2011) [10] evaluated in the IARC case-control study
(2006–2012).
(DOCX)
S5 Table. Assessment of the haemolysis-related miRNAs in lung cancer patients as com-
pared with controls in the IARC case-control study (2006–2012).
(DOCX)
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